Holds office U.S. Senate
S.1276 - Cannabidiol Research Expansion Act (2017-18)
S. 3269 Cannabidiol Research Expansion Act (2015-16)
Both Chairman Chuck Grassley and Sen. Dianne Feinstein, the ranking Democrat, said there's been an evolving standard in society and the committee is adjusting to it.
"If that's the sole judgment on whether somebody ought to have a judgeship or not - or maybe any other position - we may not be able to find people to fill those positions," said Mr. Grassley, Iowa Republican, adding that his own views on drug use have changed since he came to Congress three decades ago.
"Our country is in the middle of an epidemic of addiction focused on heroin and prescription opioids," he said. "And just last year, the Centers for Disease Control found that people who are addicted to marijuana are three times more likely to be addicted to heroin. So if the Obama Administration is serious about addressing this epidemic, it should stop burying its head in the sand about what's happening to its enforcement priorities on recreational marijuana."
"I oppose moving marijuana from a Schedule I to a Schedule II drug, based on the current science on the risks and benefits," Grassley wrote in a statement released by his staff. "Recent studies suggest marijuana use by young people can cause long-term and possibly permanent damage to brain development."
However, he said, "for children suffering from severe epileptic seizures, the anecdotal evidence says components of the marijuana plant might help. I want to help those children. The key is aggressive medical research."
"Marijuana is a dangerous and addictive drug," said Grassley, who turns 80 next week. "It's illegal under international law as well, and the treaty requires us to restrict its use to scientific and medical uses. These [legalization] laws flatly contradict our federal law. Some experts fear a Big Marijuana, a Starbucks of marijuana," he lamented.
135 Hart Senate Office Building
Washington, DC 20510